Related Experiment Videos
Linezolid
1Department of Infection, St Thomas' Hospital, London, UK.
Abstract:
Multiple antibiotic resistance is increasing worldwide in Gram-positive bacteria, especially in hospitals. Problem organisms include multiply resistant strains of pneumococci, Staphylococcus aureus and enterococci; for many of these the glycopeptide vancomycin has become the treatment of last resort. This situation has been made worse by the emergence of vancomycin-resistant enterococci and vancomycin-intermediate S. aureus. Fortunately, several compounds active against resistant Gram-positive bacteria are in active development. One of these is linezolid, the first of the oxazolidinones, a new class of antibacterial. Linezolid is a synthetic agent which is active against all the clinically important Gram-positive bacteria, including multiply resistant strains. It has good pharmacokinetics, with equal bioavailability by both oral and intravenous routes and no need for dose adjustment in patients with renal impairment. The drug has a good safety profile and clinical trials have given excellent results in a variety of skin and soft tissue, respiratory and bloodstream infections. Linezolid is a promising drug, which, together with prudent antibiotic use and the prevention and control of hospital infection, will help in the battle against multiply antibiotic resistant Gram-positive bacteria.
Insights
Linezolid, a novel oxazolidinone antibiotic, shows efficacy against multidrug-resistant Gram-positive bacteria, including hospital-acquired infections. Its favorable pharmacokinetics and safety profile make it a promising option for treating resistant infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Rising global antibiotic resistance in Gram-positive bacteria, particularly in hospital settings.
- Emergence of vancomycin-resistant enterococci and vancomycin-intermediate Staphylococcus aureus necessitates new therapeutic options.
- Glycopeptides like vancomycin are often last-resort treatments for resistant Gram-positive infections.
Purpose of the Study:
- To introduce linezolid, a novel oxazolidinone antibiotic, as a potential treatment for multidrug-resistant Gram-positive bacteria.
- To highlight linezolid's activity against clinically significant resistant Gram-positive pathogens.
- To review linezolid's pharmacokinetic properties, safety profile, and clinical trial outcomes.
Main Methods:
- Review of linezolid's chemical properties and mechanism of action.
- Analysis of in vitro activity against resistant Gram-positive strains.
- Evaluation of pharmacokinetic data, including bioavailability and dosing considerations.
- Summary of clinical trial results for various infection types.
Main Results:
- Linezolid demonstrates broad-spectrum activity against all clinically important Gram-positive bacteria, including resistant strains.
- The drug exhibits favorable pharmacokinetics with equal oral and intravenous bioavailability and no renal dose adjustment needed.
- Clinical trials show excellent efficacy in treating skin and soft tissue, respiratory, and bloodstream infections.
- Linezolid possesses a good safety profile.
Conclusions:
- Linezolid represents a significant advancement in the treatment of multidrug-resistant Gram-positive bacterial infections.
- Its efficacy, safety, and pharmacokinetic advantages position it as a valuable therapeutic agent.
- Combined with infection control and judicious antibiotic stewardship, linezolid can aid in combating resistant Gram-positive bacteria.